Truist Financial Forecasts Strong Price Appreciation for Integer (NYSE:ITGR) Stock

Integer (NYSE:ITGR) had its target price lifted by equities researchers at Truist Financial from $95.00 to $97.00 in a research report issued on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the medical equipment provider’s stock. Truist Financial’s price target indicates a potential upside of 12.80% from the stock’s previous close.

Several other research firms have also commented on ITGR. Benchmark reiterated a “hold” rating on shares of Integer in a research report on Friday, October 24th. Piper Sandler dropped their target price on Integer from $155.00 to $82.00 and set an “overweight” rating for the company in a report on Friday, October 24th. Argus downgraded Integer from a “buy” rating to a “hold” rating in a research report on Friday, October 24th. Citigroup restated a “neutral” rating on shares of Integer in a research report on Friday. Finally, Raymond James Financial reiterated an “outperform” rating and set a $95.00 price objective (down previously from $143.00) on shares of Integer in a research report on Friday, October 24th. Four investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $98.63.

Integer Price Performance

ITGR traded up $2.99 during trading hours on Friday, hitting $85.99. The company’s stock had a trading volume of 87,973 shares, compared to its average volume of 772,827. The stock has a market cap of $3.01 billion, a price-to-earnings ratio of 36.08, a P/E/G ratio of 0.80 and a beta of 0.77. The business’s 50-day moving average price is $82.58 and its 200-day moving average price is $88.41. The company has a current ratio of 3.71, a quick ratio of 2.45 and a debt-to-equity ratio of 0.70. Integer has a 12 month low of $62.00 and a 12 month high of $136.06.

Integer (NYSE:ITGR) last released its quarterly earnings data on Thursday, February 19th. The medical equipment provider reported $1.76 EPS for the quarter, beating the consensus estimate of $1.70 by $0.06. Integer had a net margin of 4.75% and a return on equity of 12.84%. The business had revenue of $472.06 million during the quarter, compared to analyst estimates of $462.73 million. During the same quarter last year, the business earned $1.43 earnings per share. Integer’s quarterly revenue was up 5.0% compared to the same quarter last year. Integer has set its FY 2026 guidance at 6.290-6.780 EPS. Sell-side analysts expect that Integer will post 6.01 earnings per share for the current fiscal year.

Integer declared that its Board of Directors has approved a share buyback program on Tuesday, November 4th that authorizes the company to buyback $200.00 million in outstanding shares. This buyback authorization authorizes the medical equipment provider to repurchase up to 8.3% of its shares through open market purchases. Shares buyback programs are usually an indication that the company’s board believes its stock is undervalued.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Tudor Investment Corp ET AL increased its holdings in Integer by 50,787.5% during the 3rd quarter. Tudor Investment Corp ET AL now owns 29,500,000 shares of the medical equipment provider’s stock worth $28,606,000 after purchasing an additional 29,442,029 shares during the period. Irenic Capital Management LP bought a new position in shares of Integer during the 4th quarter worth $99,109,000. Alliancebernstein L.P. increased its stake in shares of Integer by 885.1% during the second quarter. Alliancebernstein L.P. now owns 1,106,091 shares of the medical equipment provider’s stock valued at $136,016,000 after buying an additional 993,810 shares during the period. Millennium Management LLC raised its holdings in shares of Integer by 3,350.2% in the fourth quarter. Millennium Management LLC now owns 677,108 shares of the medical equipment provider’s stock valued at $53,106,000 after acquiring an additional 657,483 shares in the last quarter. Finally, J. Goldman & Co LP purchased a new stake in Integer in the fourth quarter worth about $40,531,000. Institutional investors own 99.29% of the company’s stock.

Key Headlines Impacting Integer

Here are the key news stories impacting Integer this week:

• Positive Sentiment: Q4 beat on revenue and EPS: Integer reported Q4 EPS of $1.76 vs. consensus ~$1.70 and revenue of $472.1M vs. ~$462.7M, with revenue +5% YoY. The beat and year-over-year growth are the immediate bullish catalyst. Press Release
• Positive Sentiment: FY2026 guidance supports upside vs. Street: Integer set FY2026 EPS guidance of $6.29–$6.78; the midpoint (~$6.54) is above the consensus ~6.31, and revenue guidance of $1.8B–$1.9B meets/edges past Street estimates — a constructive sign for forward earnings expectations. GlobeNewswire Release
• Positive Sentiment: Strong full-year performance and multi-year targets: Integer delivered ~8% sales growth and ~21% adjusted EPS growth in FY2025 and reiterated targets to outgrow the market by ~200bps in 2027 — supports medium-term growth thesis. GlobeNewswire Release
• Neutral Sentiment: Management commentary and slide deck available for detail — investors are reviewing the earnings presentation and call transcript for margin trajectory, book-to-bill and product mix drivers. These materials provide color but no major surprises so far. Earnings Presentation Call Transcript
• Negative Sentiment: Guidance range and margin/valuation considerations leave room for caution: the EPS range is fairly wide and the low end (~$6.29) is roughly flat with Street estimates, creating short-term uncertainty; operating margin (net margin ~4.75%) and a relatively high P/E may keep some investors cautious. Zacks Coverage

About Integer

Integer Holdings Corporation (NYSE: ITGR) is a global provider of outsourced medical device design, development and manufacturing solutions. The company partners with leading medical technology firms to deliver complex components, subsystems and finished devices across a range of therapeutic areas. Its services encompass concept and product design, precision machining, microelectronic assembly, terminal sterilization and regulatory support, enabling customers to accelerate time to market and optimize product performance.

Integer’s product portfolio is organized into two core segments: Advanced Delivery and MedTech.